PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0231
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		2006-06-01
First Named Inventor Shini		chiro Yamada
Art Unit		
Examiner Name		
Attorney Docket Number		09792909-6492

U.S.PATENTS		Remove									
Examiner Initial*	Cite No Patent Number Kind Code <sup>1</sup> Is		Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication e <sup>1</sup> Date		Name of Pate of cited Docu	entee or Applicant Rele			Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publ		,		n information p		d button	Add		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	,	Kind Code4	Publication	Name of Patente Applicant of cited Document	or ,	Pages,Col	or Relevant	+-
	1	2003-192925	JP			2003-07-09	Sony Corp				С
	2	2002-302613	JР			2002-10-18	Ishizuka Garasu Kabushiki Kaisha				С
	3	2003-327842	JP			2003-11-19	Ishizuka Garasu Kabushiki Kaisha				С

# Application Number | Filing Date | 2006-06-01 | First Named Inventor | Shanchiro Yamada | Art Unit | Examiner Name | Attorney Coket Number | 69792090-6492

If you win	h to a	additional Foreign Patent Document citation information please click the Add button Add	_
ii you wisi	n w a	additional Foreign Facility Decorrection Control of the Facility Decore	
		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dity and/or country where published.	Ţs
	1	International Search Report dated February 22, 2005	
If you wish	h to a	additional non-patent literature document citation information please click the Add button Add	
		EXAMINER SIGNATURE	
Examiner	Signa	ure Date Considered	
*EVALUE	FD: 1-	to Market and the state of the	_

1 See Kin Codes of USPTO Patent Documents at water USETO.GGM/or MPEP 901.04. 2 Enter office that issued the document, by the hor-letter code (WIPO Standard ST3.) 3 for Supanese patent during which is supported by the series of the pagent or may precede the sent and uniform of the pagent of the pagent or may precede the sent and uniform of the pagent of the pagent or may precede the sent and uniform of the pagent of the pagent or may precede the sent and uniform of the pagent of the pagen

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# Application Number Fing Date 2006-06-01 First Number (Not for submission under 37 CFR 1-99) Application Number 2006-06-01 First Number (Not for submission under 37 CFR 1-99) At Unit Examiner Name Attorney Docket Number (1973/2009-6492)

### CERTIFICATION STATEMENT

Diagra can	37 CFR	1 97 and 1 9	38 to make the	annronniata	coloction(c)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David R. Metzger/	Date (YYYY-MM-DD)	2006-06-01
Name/Print	David R. Metzger	Registration Number	32919

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organized to Complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, V.S. Organized to Comment of Comment

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.